Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data.

Authors:
Eun Bong Lee
Eun Bong Lee
Seoul National University College of Medicine
South Korea
Hisashi Yamanaka
Hisashi Yamanaka
Institute of Rheumatology
Hollywood | United States
Yi Liu
Yi Liu
West China Hospital
Nanchong Shi | China
Connie Chen
Connie Chen
University of Toronto
Canada
Kenneth Kwok
Kenneth Kwok
National University of Singapore
Singapore

Int J Rheum Dis 2019 Mar 22. Epub 2019 Mar 22.

University of Occupational and Environmental Health Japan, Kitakyushu, Japan.

Aim: We report tofacitinib efficacy and safety in Asia-Pacific patients who participated in the rheumatoid arthritis (RA) clinical development program.

Method: This post-hoc analysis included pooled data from patients with RA in the Asia-Pacific region treated with tofacitinib with/without conventional synthetic disease-modifying antirheumatic drugs in Phase (P)1, 2, 3, and long-term extension (LTE) studies (one LTE ongoing; January 2016 data-cut). Efficacy was assessed over 24 months in patients who received tofacitinib 5 (N = 397) or 10 (N = 382) mg twice daily or placebo (N = 243) in three P2 and five P3 studies. Endpoints included American College of Rheumatology (ACR)20/50/70 responses, Disease Activity Score in 28 joints, erythrocyte sedimentation rate (DAS28-4[ESR]) and Clinical Disease Activity Index (CDAI) remission rates, and change from baseline in Health Assessment Questionnaire-Disability Index (∆HAQ-DI). Safety data pooled over 92 months from one P1, four P2, six P3, and two LTE studies for all tofacitinib doses (N = 1464) included incidence rates (IRs) (patients with events/100 patient-years) for adverse events (AEs) of special interest.

Results: At month 3, patients receiving tofacitinib 5/10 mg twice daily improved vs placebo in ACR20 (69.2%/77.9% vs 27.5%), ACR50 (36.9%/44.4% vs 9.5%), and ACR70 (15.1%/22.4% vs 2.7%) responses, remission rates for DAS28-4(ESR) (8.5%/18.5% vs 2.6%) and CDAI (6.1%/12.3% vs 0.5%), and ∆HAQ-DI (-0.5/-0.6 vs -0.1); improvements were sustained through 24 months. IRs (95% CI) were 9.4 (8.5, 10.3) for serious AEs, 9.1 (8.3, 10.1) for discontinuations due to AEs, 3.7 (3.2, 4.3) for serious infections, 5.9 (5.2, 6.7) for herpes zoster, and 0.8 (0.6, 1.1) for malignancies (excluding non-melanoma skin cancer).

Conclusion: In Asia-Pacific patients, tofacitinib improved signs/symptoms over 24 months. Safety over 92 months was generally consistent with global tofacitinib studies; however, infection IRs were higher in Asia-Pacific patients.

Download full-text PDF

Source
http://dx.doi.org/10.1111/1756-185X.13516DOI Listing
March 2019
4 Reads

Publication Analysis

Top Keywords

asia-pacific patients
12
patients asia-pacific
8
rheumatoid arthritis
8
asia-pacific region
8
disease activity
8
lte studies
8
remission rates
8
patients
8
efficacy safety
8
tofacitinib
8
asia-pacific
5
patients events/100
4
events/100 patient-years
4
patient-years adverse
4
doses n = 1464
4
irs patients
4
included incidence
4
adverse events
4
rates irs
4
n = 1464 included
4

References

(Supplied by CrossRef)

Similar Publications